Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern TimeGlobeNewsWire • 07/21/22
Lantheus Holdings (LNTH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 06/13/22
Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in CancerGlobeNewsWire • 06/13/22
Lantheus' PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate CancerGlobeNewsWire • 06/13/22
How Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 27%Zacks Investment Research • 06/09/22
Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual MeetingGlobeNewsWire • 05/26/22
Wall Street Analysts Predict a 44% Upside in Lantheus Holdings (LNTH): Here's What You Should KnowZacks Investment Research • 05/20/22
Lantheus Holdings (LNTH) Is a Great Choice for "Trend" Investors, Here's WhyZacks Investment Research • 05/16/22
Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual MeetingGlobeNewsWire • 05/16/22
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) PatientsGlobeNewsWire • 05/13/22
Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate CancerGlobeNewsWire • 05/11/22
Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/29/22
Lantheus Holdings (LNTH) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 04/22/22